ILF2 acts as a tumor promoter, with overexpression associated with poor prognosis in CC, pancreatic ductal adenocarcinoma, non-small cell lung cancer and breast cancer (28, 65). This evidence concerns the gene ILF2 and non-small cell lung carcinoma.